Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726227 · ClinicalTrials.gov registry record · Phase 3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 20
- Study locations
NCT05726227: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT05726227 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 210 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05726227, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).
Primary Outcome
Measured in percentage (%)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
Louisiana
- Pennington Biom Res Ctr - Baton Rouge
- Clinical Trials of America LLC - Monroe
- IMA Clinical Research - Monroe
Georgia
- Columbus Research Foundation - Columbus
- Eastside Bariatric and Gen Surg - Snellville
Mississippi
- Mississippi Center for Advanced Medicine - Madison
- Mississippi CTR for ADV MED - Madison
Tennessee
- Vanderbilt University Medical Center - Nashville
- Tullahoma Pediatrics PLLC - Tullahoma
California
- Neighborhood Healthcare - Escondido
Connecticut
- Yale School of Medicine - New Haven
Idaho
- Solaris Clinical Research - Meridian
Maryland
- Barry J. Reiner, MD LLC - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2026-12-07 |
| Phase | Phase 3 |
What the registry record for NCT05726227 still lists
NCT05726227 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05726227 names 20 study sites across 15 states, led by Louisiana, Georgia, Mississippi.
Frequently Asked Questions
What is clinical trial NCT05726227 about?
NCT05726227 is a clinical study titled "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight". This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and th...
What is the current status of trial NCT05726227?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2023-07-07. Estimated completion is 2026-12-07.
What conditions does trial NCT05726227 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05726227?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05726227?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726227 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05726227's enrollment target sits among peer trials
210 303rd of 1053 higher than 748 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI